prostate cancer prostate malignancy
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Part A: 1. Histologically proven metastasised prostate cancer 2. Written informed consent 3. At least 2 tumours (metastases) per patient detected by conventional imaging (e.g., bone scan, CT or MRI of the chest, abdomen or pelvic region); conventional imaging should be recently performed (no longer than 3 months previous to the PET-CT scan) 4. At least one tumour (metastasis) with a diameter equal or more than 1.5 cm (to minimize partial volume effects) 5. Patients able to remain supine for 50 minutes in the PET-CT scanner Part B: 1. Histologically proven metastasised prostate cancer 2. Written informed consent 3. At least one tumour (metastasis) with a diameter equal or more than 1.5 cm detected by recently performed conventional imaging (maximal 3 months prior to the PET-CT scan) 4. Patients able to remain supine for 60 minutes in the PET-CT scanner
Exclusion criteria
Exclusion criteria: 1. Claustrophobia (part A and B); 2. Multiple malignancies (part A and B); 3. Anticoagulant therapy (part A).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part A: A pharmacokinetic model for [18F]FCH and an appropriate simplified quantitative method. Part B: Test-retest variability of the simplified method of choice (part A) implemented in WB [18F]FCH PET-CT. | — |
Secondary
| Measure | Time frame |
|---|---|
| To identify an appropriate simplified quantitative method for clinical practice. | — |
Countries
Netherlands
Outcome results
None listed